表紙:アプタマーの世界市場:業界動向、市場シェア・規模・成長率・機会および予測(2021年~2026年)
市場調査レポート
商品コード
1037188

アプタマーの世界市場:業界動向、市場シェア・規模・成長率・機会および予測(2021年~2026年)

Aptamers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 141 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.85円
アプタマーの世界市場:業界動向、市場シェア・規模・成長率・機会および予測(2021年~2026年)
出版日: 2021年11月10日
発行: IMARC Services Private Limited
ページ情報: 英文 141 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のアプタマーの市場規模は、2020年に43億米ドルに達し、2021年から2026年の間に約20%のCAGRで市場が成長すると予想されています。

世界のアプタマー市場の動向

  • 癌、神経変性疾患、心血管疾患、後天性免疫不全症候群(AIDS)などの生命を脅かす疾患の増加は、アプタマー療法に基づく新しい効果的な検出アッセイの需要に影響を与える主要な要因の1つとなっています。さらに、アプタマーのヌクレアーゼ耐性を高め、治療特性を強化するための化学修飾プロセスの出現が、市場成長を後押ししています。また、アプタマー市場の成長は、診断機器や医薬品、その担体を改良するために行われる研究開発(R&D)活動の増加にも起因しています。また、アプタマーは化学的に合成されるため、バッチ間のばらつきがなく、開発期間も短くて済むことから、その用途は世界中で広く拡大しています。さらに、民間企業は、次世代製品の導入や既存市場の拡大のために、学術機関や研究所と協力しています。これにより、幅広い医療分野や食品・飲料業界でのアプタマーの利用が促進されると見込まれています。

当レポートは、世界のアプタマー市場について調査しており、業界動向、市場予測、タイプ・アプリケーション・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。また、 COVID-19の不確実性を念頭に置いて、さまざまな最終用途産業に対するパンデミックの直接的および間接的な影響を継続的に追跡および評価しています 。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のアプタマー市場

  • 市場概要
  • 市場実績
  • COVID-19の影響

第6章 タイプ別の市場セグメンテーション

  • 核酸
  • ペプチド

第7章 アプリケーション別の市場セグメンテーション

  • 診断
  • 治療
  • 研究開発
  • その他

第8章 地域別の市場セグメンテーション

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 国別の市場セグメンテーション

第9章 SWOT分析

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Aptagen LLC
    • Aptamer Group
    • Aptamer Sciences Inc.
    • Aptus Biotech S.L.
    • Base Pair Biotechnologies Inc.
    • IBA GmbH
    • Kaneka Eurogentec S.A.(Kaneka Corporation)
    • NeoVentures Biotechnology Inc.
    • NOXXON Pharma
    • SomaLogic Inc.
    • TriLink BioTechnologies LLC
    • Vivonics Inc.
目次
Product Code: SR1020G209_Report

The global aptamers market reached a value of US$ 4.3 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 20% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Aptamers are versatile oligonucleotides that bind to a specific target, including proteins, peptides, carbohydrates, small molecules, toxins, and live cells. They are modifiable, nonimmunogenic, highly sensitive, less toxic, easy to prepare and have low molecular weight and no variation with different preparations as compared to antibodies. As a result, they are widely being used in therapeutic and biotechnological applications. Besides this, they are also utilized as research agents, diagnostics, biosensors, and tools for biomarker or drug discovery worldwide.

Global Aptamers Market Trends:

The growing prevalence of life-threatening diseases, such as cancer, neurodegenerative, cardiovascular, and acquired immunodeficiency syndrome (AIDS), represents one of the key factors influencing the demand for new and effective detection assays based on aptamer therapy. Moreover, the advent of the chemical modification process to increase the nuclease resistance and enhance the therapeutic properties of aptamers is bolstering the market growth. The aptamers market growth can also be accredited to the rising number of research and development (R&D) activities undertaken for improving diagnostic devices and drugs and their carriers. Apart from this, as aptamers are chemically synthesized, which eliminates batch-to-batch variation and requires less time for development, their application is extensively increasing across the globe. Furthermore, private organizations are collaborating with academic institutes and research laboratories to introduce next-generation products and expand their existing market presence. This is anticipated to fuel the usage of aptamers in a wide range of medical therapies, as well as in the food and beverage (F&B) industry.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global aptamers market, along with forecasts at the global, regional and country-level from 2021-2026. Our report has categorized the market based on type and application.

Breakup by Type:

  • Nucleic Acid
  • Peptide

Breakup by Application:

  • Diagnostics
  • Therapeutics
  • Research and Developments
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Aptagen LLC, Aptamer Group, Aptamer Sciences Inc., Aptus Biotech S.L., Base Pair Biotechnologies Inc., IBA GmbH, Kaneka Eurogentec S.A. (Kaneka Corporation), NeoVentures Biotechnology Inc., NOXXON Pharma, SomaLogic Inc., TriLink BioTechnologies LLC and Vivonics Inc.

Key Questions Answered in This Report:

  • How has the global aptamers market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global aptamers market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global aptamers market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Aptamers Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Nucleic Acid
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Peptide
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Diagnostics
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Therapeutics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Research and Developments
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Aptagen LLC
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
    • 13.3.2 Aptamer Group
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Aptamer Sciences Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Aptus Biotech S.L.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
    • 13.3.5 Base Pair Biotechnologies Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 IBA GmbH
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
    • 13.3.7 Kaneka Eurogentec S.A. (Kaneka Corporation)
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 NeoVentures Biotechnology Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 NOXXON Pharma
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
    • 13.3.10 SomaLogic Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
    • 13.3.11 TriLink BioTechnologies LLC
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
    • 13.3.12 Vivonics Inc.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio